Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkaf471 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Aleece MacPhail und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Glycopeptides, Gram-Positive Bacterial Infections, Health Services Accessibility. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Long-acting glycopeptide antibiotics (LGPs), such as dalbavancin and oritavancin, are a novel class of antibiotic agents effective in the treatment of Gram-positive infections. The long half-life and relative ease of administration of LGPs make them a valuable treatment option for patients experiencing barriers to healthcare access. However, challenges for effective use remain, and disproportionately affect patients who would most benefit. These include high upfront costs, cost siloing, impractical and inconsistent medication approval processes and limited integration into existing multidisciplinary models of care. There is a clear need to improve funding arrangements, institutional workflows and models of care to promote safe and equitable access to LGPs, in line with processes developed for other high-cost medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
- Monash Infectious Diseases, Monash Health, 246 Clayton Road, Clayton, Melbourne, Australia.
- Hospital in the Home Program, Monash Health, 246 Clayton Road, Clayton, Melbourne, Australia.
ORCID-Profile: Aleece MacPhail, Lucy O Attwood, Benjamin A Rogers
Zitieren
APA
MacPhail, A., Attwood, L. O., & Rogers, B. A. (2026). Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf471
Vancouver
MacPhail A, Attwood LO, Rogers BA. Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf471
BibTeX
@article{MacPhail2026,
author = {MacPhail, Aleece and Attwood, Lucy O and Rogers, Benjamin A},
title = {Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkaf471}
}
EUVIMED